Heron Therapeutics, Inc. (HRTX) Stock Forecast
HRTX analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.00 / 5 from 2 analysts
- Price target
- $7.00 average of analyst targets
- Upside to target
- +1,839.1% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.03
- 52-week range
- $0.27 – $1.49
HRTX analyst ratings
2 analystsNumber of analysts at each rating.
HRTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
HRTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.03 | −$0.03 | −$0.02 | −$0.04 | +30.8% | 2 |
| Current fiscal year (2026) | −$0.13 | −$0.14 | −$0.12 | −$0.05 | −144.8% | 2 |
| Next fiscal year (2027) | −$0.11 | −$0.12 | −$0.10 | −$0.13 | +15.4% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
HRTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $37.5M | $37.4M | $37.6M | −1.9% | 2 |
| Current fiscal year (2026) | $148.2M | $147.7M | $148.8M | −4.3% | 2 |
| Next fiscal year (2027) | $145.9M | $145.8M | $146.0M | −1.6% | 2 |
HRTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
HRTX revenue: reported and forecast
HRTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.02 | −$0.02 | −$0.02 | −$0.02 | −$0.03 | +25.0% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.09 | −$0.09 | −$0.09 | −$0.09 | −$0.13 | +44.4% | 0 up · 1 down |
| Next fiscal year (2027) | $0.00 | $0.00 | $0.00 | $0.00 | −$0.11 | — | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
HRTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; HRTX beat in 7 of 12.
What analysts expect from HRTX
2 analysts cover Heron Therapeutics; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.00, 1,839.1% above the latest close of $0.36. Analysts expect earnings of −$0.13 per share for 2026, −144.8% from a year earlier. For 2027 the average estimate is −$0.11 per share on revenue of $145.9 million. Heron Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: HRTX income statement, HRTX key metrics, HRTX chart. See the HRTX stock overview for the latest quote and news.
HRTX forecast FAQ
What is Heron Therapeutics's price target?
The average analyst price target for Heron Therapeutics is $7.00, 1,839.1% above the latest close of $0.36.
Is Heron Therapeutics a buy, hold or sell?
Of 2 analysts covering Heron Therapeutics, 0 rate it a strong buy, 0 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Heron Therapeutics's EPS forecast?
Analysts forecast −$0.13 per share for 2026 (range −$0.14 to −$0.12); for 2027 the estimate is −$0.11.
What is Heron Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $148.2 million, growth of −4.3%; for 2027 it is $145.9 million.
When does Heron Therapeutics report earnings?
Heron Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens; the EPS estimate is $-0.03.
Does Heron Therapeutics usually beat earnings estimates?
Heron Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.